Schrodinger, Inc. (SDGR) Stock Price & Analysis

Schrodinger, Inc. (SDGR) fell 2.99% to USD 20.09 as of September 8, 2026 at 05:47 UTC, according to Nexqual real-time market data.

SDGR last closed at USD 20.09; the session ranged USD 19.69–20.67 on volume of 877,064 shares. Market capitalization is —, with a 52-week range of USD 10.95–23.02 (NMS). Source: Nexqual, September 8, 2026 at 05:47 UTC.

Key Statistics (as of September 8, 2026 at 05:47 UTC)

Technical Analysis (SDGR)

Nexqual's technical model rates SDGR "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:47 UTC.

From Schrodinger, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform Over the past several decades since our founding in 1990, and with the concerted effort of hundreds of our scientists and software engineers, we have developed a computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy.
• Our Proprietary Drug Discovery Programs In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics.
• The following is a summary of our proprietary drug discovery programs: Our Approach to Target Selection Our selection of targets is based on an extensive analysis of human targets and drug discovery programs.
• In June 2025, the FDA granted fast track designation for SGR-1505 for the treatment of adult patients with Waldenström macroglobulinemia, or WM, that have failed at least two lines of therapy, including a Bruton's tyrosine kinase, or BTK, inhibitor.

Partnerships

• For example, in November 2024, we entered into an expanded, three-year, software agreement with Novartis, which is more fully described in "— Collaboration Agreements ." The three-year agreement substantially increases Novartis' access to our computational predictive modeling technology and enterprise informatics platform to industry-leading scale.
• We are eligible to receive up to $2.272 billion in total milestones across the initial programs, of which no milestone revenue has been recognized as revenue as of December 31, 2025, as well as a tiered percentage royalty on net sales of each product commercialized by Novartis ranging from mid-single-digits to low double-digits, subject to certain specified reductions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:47 UTC. This page is informational and not investment advice.